Investigative Ophthalmology & Visual Science Cover Image for Volume 61, Issue 7
June 2020
Volume 61, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2020
The impact of changes at the vireoretinal interface and retinal thickness following the administration of a single 0.19 mg fluocinolone acetonide (FAc, ILUVIEN) device, implanted after partial PPV in patients with persistent or recurrent DME – results from the ILUVIT study, a single center, phase IV study.
Author Affiliations & Notes
  • Frank H J Koch
    Retina and Vitreous Unit, University Eye Clinic Frankfurt / Main, Frankfurt am Main, Germany
  • Pankaj Singh
    Retina and Vitreous Unit, University Eye Clinic Frankfurt / Main, Frankfurt am Main, Germany
  • Adonis Chedid
    Retina and Vitreous Unit, University Eye Clinic Frankfurt / Main, Frankfurt am Main, Germany
  • Natallia Brui
    Retina and Vitreous Unit, University Eye Clinic Frankfurt / Main, Frankfurt am Main, Germany
  • Thomas Kohnen
    University Eye Clinic, Frankfurt am Main, Germany
  • Hanns Ackermann
    Insitute of Biostatistics, Goethe-University, Frankfurt am Main, Germany
  • Svenja Deuchler
    Retina and Vitreous Unit, University Eye Clinic Frankfurt / Main, Frankfurt am Main, Germany
  • Footnotes
    Commercial Relationships   Frank Koch, Alimera (F); Pankaj Singh, Alimera (F); Adonis Chedid, Alimera (F); Natallia Brui, Alimera (F); Thomas Kohnen, Alimera (F); Hanns Ackermann, None; Svenja Deuchler, Alimera (F)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 4870. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Frank H J Koch, Pankaj Singh, Adonis Chedid, Natallia Brui, Thomas Kohnen, Hanns Ackermann, Svenja Deuchler; The impact of changes at the vireoretinal interface and retinal thickness following the administration of a single 0.19 mg fluocinolone acetonide (FAc, ILUVIEN) device, implanted after partial PPV in patients with persistent or recurrent DME – results from the ILUVIT study, a single center, phase IV study.. Invest. Ophthalmol. Vis. Sci. 2020;61(7):4870.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Abnormalities of the vitreoretinal interface can reduce the effectiveness of intravitreal therapies. The ILUVIT study aimed to measure intravitreal inflammatory and angiogenic cytokine levels prior to and following the intravitreal injection of the FAc implant. Here we also assess the concurrent changes in the vitreoretinal interface and retinal thickness.

Methods : The single center phase IV investigator initiated ILUVIT study was conducted at the University of Frankfurt in Germany and approved by BfARM (EudraCT-Number: 2016-004488-38). It is a study to assess cytokine and chemokine expression patterns in 12 patient eyes with diabetic macula edema (DME), partial vitrectomy (pPPV) was performed prior to (month 0) and following therapy (month 1 and 6) with a single FAc implant and changes in the vitreoretinal interface (using OCT and B-scan ultrasonography) as well as changes in central (CRT) and average (ART) retinal thickness were measured. Exploratory analysis focused on outcomes based on the presence (n=7) or absence (n=5) of vitreoretinal traction.

Results : When divided based on the presence of vitreoretinal traction, the starting CRT was higher (468±106 µm vs. 326±173 µm [presence vs. absence]). During the study the majority (86%) of patients eyes with initial vitreoretinal traction developed a PVD after performing pPPV. The combination of PVD and the FAc implant led to significant reductions in CRT (-134.43 µm, p=0.0005) and ART (-39.08 µm, p= 0.01). In contrast, the absence of vitreoretinal traction led to pronounced changes in CRT (-65.4 µm, p=0.24) and ART (-35.62 µm, p=0.165).
Analyses of cytokine and chemokine expression showed the FAc implant led to consistent changes (i.e. >20% change from baseline) in IP-10, MCP-1, and CD-54 in both groups, but not for IL-6, IL-8, VEGF and PIGF, where changes (>20% from baseline) were only observed in the absence of vitreoretinal traction at baseline.

Conclusions : In this exploratory analysis, pPPV, which leads to partial reduction of vitreous volume and separation from the retinal surface, positively affected the course of DME in the patients studied.

This is a 2020 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×